Ironwood Pharmaceuti (IRWD) 14.24 $IRWD Aegerion (AEGR):

New Post Public Reply Private Reply Replies (0) Message Board

Aug 1, 2016 at 12:06 PM

Ironwood Pharmaceuti (IRWD) 14.24 $IRWD

Aegerion (AEGR): What Awaits for the Stock in Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - 2 hrs 3 mins ago
Aegerion (AEGR) is expected to report second-quarter 2016 results on Aug 3.
IPXL: 31.44 (+0.02), IRWD: 14.24 (+0.11), AEGR: 1.48 (+0.04), EXEL: 9.28 (+0.10)

Keryx (KERX) Q2 Earnings Preview: Will the Stock Gain?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 4:13PM CDT
Keryx Biopharmaceuticals, Inc. (KERX) is expected to report second-quarter 2016 results on Aug 3.
IPXL: 31.44 (+0.02), IRWD: 14.24 (+0.11), KERX: 5.18 (-2.18), EXEL: 9.28 (+0.10)

What's in Store for Prothena (PRTA) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 3:44PM CDT
Prothena Corporation plc (PRTA) is expected to report second-quarter 2016 results on Aug 2.
IPXL: 31.44 (+0.02), IRWD: 14.24 (+0.11), PRTA: 56.17 (+1.12), EXEL: 9.28 (+0.10)

Whta's in Store for Endocyte (ECYT) this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 9:59AM CDT
Endocyte, Inc. (ECYT) is expected to report second-quarter 2016 results on Aug 2.
IPXL: 31.44 (+0.02), ECYT: 3.23 (+0.05), IRWD: 14.24 (+0.11), EXEL: 9.28 (+0.10)

Mallinckrodt (MNK) Q3 Earnings: Will the Stock Surprise?
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 5:47PM CDT
Mallinckrodt plc (MNK) is set to report third-quarter fiscal 2016 results on Aug 2.
MNK: 67.21 (-0.13), IRWD: 14.24 (+0.11), MDCO: 39.28 (+0.17), EXEL: 9.28 (+0.10)

AmerisourceBergen (ABC) Q3 Earnings: Stock to Surprise?
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 11:10AM CDT
AmerisourceBergen Corporation (ABC) is set to report third-quarter fiscal 2016 results on Aug 2, before the opening bell.
ABC: 85.67 (+0.48), WBA: 79.29 (+0.04), IRWD: 14.24 (+0.11), BMY: 75.81 (+1.00)

McKesson (MCK) Q1 Earnings: Stock Likely to Beat?
Zacks Equity Research - Zacks Investment Research - Mon Jul 25, 5:35PM CDT
McKesson Corporation (MCK) is scheduled to report first-quarter fiscal 2017 results on Jul 27, after the market closes.
MCK: 193.62 (-0.94), IRWD: 14.24 (+0.11), BMY: 75.81 (+1.00), EXEL: 9.28 (+0.10)

Herbalife and Ironwood advance; Infosys and Fairmount drop
AP - Fri Jul 15, 3:11PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Friday:
SGYP: 4.13 (+0.05), HLF: 67.45 (-0.56), FMSA: 6.41 (-0.44), IRWD: 14.24 (+0.11), CCL: 46.65 (-0.07), C: 43.71 (-0.10), WFC: 47.76 (-0.21), INFY: 16.51 (+0.08)

First Week of February 2017 Options Trading For Ironwood Pharmaceuticals (IRWD)
DividendChannel.com - Tue Jun 21, 10:00AM CDT
Investors in Ironwood Pharmaceuticals Inc. saw new options begin trading this week, for the February 2017 expiration.
IRWD: 14.24 (+0.11)

Ironwood/Allergan's Linzess sNDA Accepted for FDA Review
Zacks Equity Research - Zacks Investment Research - Fri Jun 10, 10:31AM CDT
Ironwood (IRWD) and Allergan's (AGN) sNDA for the 72 mcg dose of Linzess for the treatment of adults with CIC has been accepted for review by the FDA.
AGN: 253.36 (+0.41), IRWD: 14.24 (+0.11), AZN: 33.95 (-0.19), JNP: 7.60 (+0.06)

Technical Analysis on Drugs - Generic Equities -- Akorn, Ironwood Pharma, Catalyst Pharma, and Pacira Pharma
PR Newswire - Fri Jun 10, 7:00AM CDT
On Thursday, June 09, 2016, the NASDAQ Composite ended the trading session at 4,958.62, down 0.32%; the Dow Jones Industrial Average edged 0.11% lower to finish at 17,985.19; and the S&P 500 closed at 2,115.48, down 0.17%. ActiveWallSt.com has initiated coverage on the following equities: Akorn Inc. (NASDAQ: AKRX), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX), and Pacira Pharmaceuticals Inc. (NASDAQ: PCRX). Learn more about these stocks by accessing their free trade alerts at:
IRWD: 14.24 (+0.11), CPRX: 0.74 (+0.02), AKRX: 34.05 (-0.18), PCRX: 37.71 (+1.46)

Ironwood and Allergan Announce Supplemental New Drug Application for 72 mcg Linaclotide in Chronic Idiopathic Constipation Has Been Accepted for FDA Review
PR Newswire - Thu Jun 09, 7:01AM CDT
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for the 72 mcg dose of linaclotide for use in the treatment of adults with chronic idiopathic constipation (CIC). The sNDA for the 72 mcg dose of linaclotide is based on efficacy and safety data from a double-blind, placebo-controlled Phase III clinical trial of 1,223 adult patients with CIC. The FDA Prescription Drug User Fee Act (PDUFA) target action date is expected to occur in early 2017.
AGN: 253.36 (+0.41), IRWD: 14.24 (+0.11)

Ironwood Pharmaceuticals to Present at Jefferies 2016 Healthcare Conference
BusinessWire - Mon Jun 06, 3:01PM CDT
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Jefferies 2016 Healthcare Conference on Friday, June 10, 2016 at 2:30 p.m. Eastern Time in New York City.
IRWD: 14.24 (+0.11)

AstraZeneca Sells Zurampic's EU and Latin American Rights
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 9:19AM CDT
AstraZeneca (AZN) entered into a licensing agreement granting Gr??nenthal the rights to its gout drug Zurampic in the EU and Latin America.
IRWD: 14.24 (+0.11), ANIP: 60.01 (-0.59), AZN: 33.95 (-0.19), BMY: 75.81 (+1.00)

Ironwood Pharmaceuticals Closes U.S. Transaction with AstraZeneca for Lesinurad
BusinessWire - Fri Jun 03, 1:00AM CDT
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that it has closed the previously-announced transaction with AstraZeneca for the exclusive U.S. rights to all products containing lesinurad. Lesinurad 200mg tablets were approved as ZURAMPIC(R) by the U.S. Food and Drug Administration (FDA) in December 2015 for use in combination with a xanthine oxidase inhibitor (XOI) for the treatment of hyperuricemia associated with uncontrolled gout. The licensing agreement includes exclusive U.S. rights to the fixed-dose combination of lesinurad and allopurinol. AstraZeneca plans to submit, on Ironwood's behalf, the fixed-dose combination program for FDA regulatory review in the second half of 2016. The agreement also includes certain rights to potentially access RDEA3170 in gout indications in the U.S.
IRWD: 14.24 (+0.11)

Ironwood Pharmaceuticals to Present at Goldman Sachs 37th Annual Global Healthcare Conference
BusinessWire - Wed Jun 01, 3:01PM CDT
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Goldman Sachs 37th Annual Global Healthcare Conference on Tuesday, June 7, 2016 at 4:00 p.m. Pacific Time/7:00 p.m. Eastern Time at the Terranea Resort in Rancho Palos Verdes, California.
IRWD: 14.24 (+0.11)

Ironwood Pharmaceuticals to Present at 2016 UBS Global Healthcare Conference
BusinessWire - Wed May 18, 3:01PM CDT
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the 2016 UBS Global Healthcare Conference on Wednesday, May 25, 2016 at 9:00 a.m. Eastern Time at the Grand Hyatt New York.
IRWD: 14.24 (+0.11)

Ironwood Pharmaceuticals to Present Linaclotide Data at Digestive Disease Week(R) 2016
BusinessWire - Tue May 17, 7:00AM CDT
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced the presentation of linaclotide-related clinical and preclinical data from the company and its collaborators during Digestive Disease Week(R) (DDW) 2016 in San Diego, CA, May 21 through May 24, 2016.
IRWD: 14.24 (+0.11)

Ironwood Pharmaceuticals Provides First Quarter 2016 Investor Update
BusinessWire - Mon May 09, 3:05PM CDT
--- LINZESS(R) (linaclotide) U.S. net sales increased ~44% to $137 million in 1Q 2016 compared to 1Q 2015; on track to exceed $1 billion in net sales by 2020 -
IRWD: 14.24 (+0.11)

Drug Stocks' Earnings Previews: FGEN, IRWD, ENTA, FLML
Zacks Equity Research - Zacks Investment Research - Fri May 06, 9:19AM CDT
However, a few companies are still yet to report quarterly numbers. Let's see what we can expect from a few drug stocks reporting earnings early next week.
BIIB: 304.90 (+14.97), ABT: 45.29 (+0.54), JNJ: 125.42 (+0.19), FLML: 12.88 (+0.37), IRWD: 14.24 (+0.11), GILD: 80.89 (+1.42), AMGN: 174.27 (+2.24), FGEN: 19.76 (+0.63), ENTA: 22.50 (+0.01), NVS: 83.18 (-0.08)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

MiniCo's New Desk: A Game Changer for E&S Market

A New Chapter in Industrial Casualty Look out, folks! MiniCo Insurance Agency is making waves with its latest launch. They're teaming up with Lloyd's of London, not to sell fish and chips, but to bring something groundbreaking in the insurance space—an industrial casualty trading desk. And if you’re raising an eyebrow wondering why this matters, let me break it down...

Nelson-Jameson Boosts Cold Storage in California Move

An Icy Boost for the West Coast Dairy Player Every now and then, a company gets its cold storage game just right. Nelson-Jameson has added fresh muscle to its Turlock facility in California, making waves with serious logistical upgrades. The company's dogged pursuit of better operational efficiency in dairy processing isn't just about bragging rights. It's plain old good...

Managed Connectivity: Key to Modern Multifamily Living

Connectivity Runs the Modern Show Imagine moving into a shiny new apartment, where the biggest hassle isn't unpacking boxes but ensuring your gadgets get online smoothly. That's the reality of today's multifamily living, where the internet is more than a utility—it's the backbone of modern life. And if you think it's just about offering internet access, you're missing...

Maternal Health Index: A New Tool With Big Ambitions

A Fresh Take on Maternal Health Today's all about the Heartland Forward's fresh tool, the Maternal Resiliency Index. It's making a splash at the 2026 Heartland Summit with a lot of promise on its shoulders. Backed by economists and health gurus like Emily Oster and Dr. Neel Shah, this index ain't your run-of-the-mill tool. It's here to shake the couch coins out of...

Ace Hardware Ups the Stakes with Rewards Days Event

Ace Hardware: Doubling Down with Rewards Ace Hardware's rolling out the red carpet for its loyal customers. Imagine this: exclusive deals on trusted brands and double points on purchases—an incentive any savvy shopper would jump at. From October 6 to 7, those in the Ace Rewards circle have the chance to nab some hefty savings and perks, a move that's more than just a...

Kroger, Imprint Team Up for AI-Driven Mastercard

Kroger Teams Up with Imprint for New Credit Card Kroger’s at it again, folks. They're rolling out a shiny new Mastercard, and it's not just any plastic—it’s powered by the AI-driven platform Imprint. Now, what does this mean for you and me? Well, if you're a frequent flyer at Kroger aisles, you might want to pay attention because this card’s offering point...

Mitsubishi's Q3 Sales: SUVs Up, Mirage Out

You ever notice how the market treats innovation and tradition like they’re these ever-spinning plates in a circus act? Take Mitsubishi Motors North America (MMNA). Their third-quarter report's got me both nodding in approval and scratching my head. Sure, they sold 18,543 vehicles—down 5.6% from the previous year. But don’t write 'em off just yet. The slumping...

Karen Love's Retirement Marks End of an Era for TACHP

A Legacy Not Just Built, But Carved in Stone In the world of healthcare, folks like Karen Love don’t come around too often. She's stepping down from her post as President and CEO of Cook Children's Health Plan this month, and it feels like the end of a chapter for the Texas Association of Community Health Plans (TACHP). Love wasn't just an executive; she was a mover and...

Texas A&M-San Antonio's Research Expansion Momentum

Texas A&M-San Antonio's Rising Research Ambitions A rainy day in San Antonio and Texas A&M University-San Antonio seems to have set the stage for more than just another semester of record enrollment. They’ve just rolled in with an exhilarating $8 million in external grants this fiscal year, more than doubling last year’s haul of $3.6 million, in a bid to push their...

SaponiQ Reinvents Body Care with Botanical Soap Bars

Breaking Through with Simple Innovation I'll be the first to say it's not every day you hear about a soap company trying to shake things up in body care like it’s a tech startup, but here’s SaponiQ taking a wild swing at it with their lineup of botanical cleansing bars. These things are whipped up in their own U.S.-based facility using some fancy cold-process...